Sangamo Therapeutics, Inc.

7000 Marina Blvd
Brisbane
CA
94005
United States

Tel: (510) 970-6000

About Sangamo Therapeutics, Inc.

Sangamo Therapeutics is a genomic medicine company building value with cutting-edge work across four distinct but complementary technology platforms – gene therapy, cell therapy, in vivo genome editing, and in vivo genome regulation. At Sangamo, we are passionate in developing genomic medicines to transform the lives of patients with serious diseases. We transform lives by building a robust, sustainable, differentiated, innovative, and high value genomic medicine pipeline that addresses patients with life-limiting conditions. Sangamo takes pride in being the first to edit endogenous human genes, first to treat patients with gene edited T cells, and first to treat patients with in vivo genome editing. Our top priority is to meet the needs of patients with commitment and compassion. Along with our commitment to science and to our patients, we also endeavor to create an inclusive environment that promotes and values diversity. Sangamo is a company where individuals can flourish, grow and develop their expertise.

We are seeking top talent to join our mission. Let’s build a better future together.

Stock Symbol: SGMO

590 articles with Sangamo Therapeutics, Inc.

Biogen and Sangamo Ink $2.7 Billion+ Neurodegeneration Deal

2/28/2020

Biogen and Sangamo Therapeutics announced a broad global licensing collaboration deal to develop and commercialize several compounds for a range of neurological and neuromuscular diseases.
Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases

2/27/2020

Biogen Inc. and Sangamo Therapeutics, Inc. announced that they have executed a global licensing collaboration agreement to develop and commercialize ST-501 for tauopathies including Alzheimer’s disease, ST-502 for synucleinopathies including Parkinson’s disease, a third undisclosed neuromuscular disease target, and up to nine additional undisclosed neurological disease targets.
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2019 Conference Call and Webcast

2/25/2020

Sangamo Therapeutics, Inc., a genomic medicine company, announced that the Company has scheduled the release of its fourth quarter and full year 2019 financial results before market opens on Friday, February 28, 2020.
Sangamo Therapeutics Appoints John Markels to Its Board of Directors

2/12/2020

Feb. 12, 2020 13:00 UTC BRISBANE, Calif.--( BUSINESS WIRE )-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of Dr. John Markels, an accomplished pharmaceutical executive with three decades of general management, manufacturing and technology experience at Merck, to the Sangamo Board of Directors. "We are very pleased to welcome John to our Board," said Sandy Macrae, Chief Executive Officer of Sangamo. “John’s manufacturi
Sangamo Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

1/9/2020

Sangamo Therapeutics, Inc., a genomic medicine company, announced that Sandy Macrae, CEO of Sangamo, will present a corporate overview at the 38th Annual J.P. Morgan Healthcare Conference on Thursday, January 16th at 8:30 a.m. PT in San Francisco.
Sangamo Announces Early Completion of Transfer to Pfizer of SB-525 Hemophilia A Gene Therapy IND and an Earned $25 Million Milestone Payment

12/23/2019

Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today the completion of the transfer to Pfizer of the SB-525 Hemophilia A gene therapy Investigational New Drug application (IND). Pfizer is advancing SB-525 into a Phase 3 registrational clinical study in 2020 and has already commenced enrolling patients into a Phase 3 lead-in study.
Sangamo Highlights Advancements in Genomic Medicine Pipeline and Expanded R&D and Manufacturing Capabilities at R&D Day

12/17/2019

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, is hosting an R&D Day today beginning at 8am Eastern Time.
Sangamo Announces Preliminary Results From the First Three Patients in a Phase 1/2 Study Evaluating ST-400 Ex Vivo Gene-edited Cell Therapy in Beta Thalassemia

12/9/2019

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced preliminary results from the first three patients treated in the Phase 1/2 THALES study evaluating investigational ST-400 ex vivo gene-edited cell therapy in transfusion-dependent beta thalassemia (TDT)
Sangamo and Pfizer Announce Updated Phase 1/2 Results Showing Sustained Increased Factor VIII Activity Through 44 Weeks Following SB-525 Gene Therapy Treatment

12/7/2019

The first two patients treated with the 3e13 vg/kg dose achieved stable Factor VIII (FVIII) levels demonstrating durability in the normal range through 44 and 37 weeks, respectively
Sangamo to Highlight Genomic Medicine Pipeline, Technology Platforms, and Manufacturing Capabilities in December 17 R&D Day

12/6/2019

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the Company plans to host an R&D Day on December 17, 2019 at 8am Eastern Time in New York City. Sangamo executives and scientists will provide updates across the Company’s clinical and preclinical pipeline of genomic medicine product candidates, offer perspective on clinical data being presented at the upcoming American Society of Hematology Annual Meeting,
BioSpace Movers & Shakers, Nov. 29

11/29/2019

Pharma and life science companies strengthen their leadership teams and boards of directors with this week's appointments.
Sangamo Therapeutics Appoints James R. Meyers to Its Board of Directors

11/26/2019

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of James R. Meyers, an accomplished pharmaceutical executive with three decades of commercial experience, to the Company's Board of Directors.
Sangamo Announces UK Authorization of a Phase 1/2 Clinical Trial Evaluating the CAR-Treg Cell Therapy TX200 for Kidney Transplantation

11/19/2019

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the United Kingdom’s (UK) Medicines Healthcare Products Regulatory Agency (MHRA) has granted authorization of the first-in-human clinical trial to evaluate a Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) therapy
Sangamo Therapeutics Announces Participation at the Jefferies 2019 London Healthcare Conference

11/18/2019

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Jefferies 2019 London Healthcare Conference on Thursday, November 21 at 4:40 p.m. GMT in London, UK.
Sangamo Therapeutics Announces New Scientific Advisory Board

11/8/2019

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that is has established a new Scientific Advisory Board (SAB)
Sangamo Therapeutics Reports Third Quarter 2019 Financial Results

11/6/2019

Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported third quarter 2019 financial results and recent business highlights
Sangamo Therapeutics Appoints Sung Lee as Executive Vice President and Chief Financial Officer

11/1/2019

Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, announced today the appointment of Sung Lee as Executive Vice President and Chief Financial Officer, effective October 31, 2019.
Sangamo Therapeutics Announces Third Quarter 2019 Conference Call and Webcast

10/30/2019

Sangamo Therapeutics, Inc., a genomic medicine company, announced that the Company has scheduled the release of its third quarter 2019 financial results after the market closes on Wednesday, November 6, 2019.
BioSpace Movers & Shakers, Oct. 4

10/4/2019

Life science and pharma companies strengthen their leadership teams with this week's appointments.
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences in October 2019

9/30/2019

Sangamo Therapeutics, Inc., a genomic medicine company, announced that members of the management team will present at the following investor and industry conferences in October